Gossamer Bio Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Gossamer Bio Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 20 Aug 2021 | Lorem |
| Gossamer Bio’s GB001 prospects in Phase IIb asthma precarious after Novartis’ fevipiprant fumble; eosinophilic subgroup to cause win unknown, experts say | 16 Jan 2020 | Manasi Vaidya |
| Gossamer Bio to welcome CRO pitches for global Phase III asthma trials in mid-2020, decisions by 2H20, CEO says | 04 Dec 2019 | Shuan Sim |
| Gossamer Bio’s Phase IIB GB001 asthma trial closing accrual in December, few patients left to enroll, investigator says | 27 Nov 2019 | Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer